CASP9 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human ovarian clear cell carcinoma line MES-OV, carrying a targeted disruption of the CASP9 gene. This polyclonal knockout pool provides a loss-of-function model for functional studies, avoiding clonal artifacts, and is supplied as a ready-to-use polyclonal population suitable for biochemical and cell-based assays.
The MES-OV host cell line models ovarian clear cell carcinoma with ARID1A deficiency, a frequent mutation in this cancer type. ARID1A loss alters chromatin remodeling and apoptotic regulation, making it a clinically relevant background for investigating CASP9 function in a disease context.
CASP9 encodes the initiator caspase-9, a central component of the intrinsic mitochondrial apoptosis pathway. Pro-apoptotic signals trigger BAX and BAK oligomerization at the outer mitochondrial membrane, causing cytochrome c release. Cytosolic cytochrome c binds APAF1, inducing its oligomerization into the apoptosome. The apoptosome recruits procaspase-9, which undergoes proximity-induced autocleavage to generate active caspase-9. This active protease cleaves and activates executioner caspases CASP3 and CASP7, which subsequently process substrates including PARP, ICAD, and Lamin A/C, driving apoptotic execution. The pathway is modulated by XIAP-mediated inhibition, competitive displacement by SMAC, and phosphorylation by kinases such as AKT and HSP27. Interacting partners like HSP70 and ARC also regulate caspase-9 activity. Disruption of CASP9 expression in this polyclonal knockout population abrogates apoptosome-dependent signal transduction, providing a clean loss-of-function model.
In the context of ARID1A-deficient ovarian clear cell carcinoma, CASP9 knockout allows precise dissection of intrinsic apoptotic signaling and its role in chemoresistance. ARID1A loss is associated with altered epigenetic regulation and apoptotic thresholds, and this knockout model enables the study of synthetic lethality strategies that target apoptotic vulnerabilities. Beyond oncology, CASP9 dysfunction is linked to neurodegenerative diseases, autoimmune lymphoproliferative syndrome, and retinal degeneration, extending the utility of this system to broader apoptosis research.
Typical research applications include characterizing intrinsic apoptosis in ovarian cancer, evaluating CASP9 function in ARID1A-mutant clear cell carcinoma, and screening pro-apoptotic therapeutics. The cells are suitable for Western blotting for CASP9 and cleaved CASP3, caspase-9 activity luminescence assays, cytochrome c release assays, annexin V/PI flow cytometry, TUNEL staining, MTT or CellTiter-Glo viability assays, clonogenic survival, and immunoprecipitation of apoptosome components. For additional details, please contact Ascent Research.
